Arunasingam Abayasingam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Arunasingam Abayasingam has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Rowena A. Bull
UNSW Sydney
3 shared publications - Andrew R. Lloyd
The Kirby Institute, University of New South Wales, Sydney, Australia
2 shared publications - Arthur Eng Lip Yeow
Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia
2 shared publications - David Agapiou
The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia
2 shared publications - David John Lynn
South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
2 shared publications - Makutiro G. Masavuli
University of Adelaide
2 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Elsevier in SSRN Electronic Journal
Integrated Serological Surveillance of Neglected Tropical Diseases in Elimination and Post-Elimination Pathways in Vanuatu
Background: Vanuatu was validated for elimination of lymphatic filariasis (LF) as a public health problem in 2016 and of trachoma in 2022, yet yaws remains endemic. Post-validation surveillance is poorly defined and disease-specific surveys costly. We assessed a multiplex serological platform embedded in prevalence surveys integrated with mass drug administration (MDA) using ivermectin, azithromycin and albendazole, as post-validation surveillance for trachoma and LF and to identify yaws transmission foci.Methods: Six cross-sectional surveys (2021–2024) in Tafea, Sanma and Shefa provinces accompanied integrated MDA. Dried blood spots (DBS) from randomly selected participants aged ≥1 year were tested by multiplex bead assay for IgG against Pgp3 (trachoma), Bm14 and Wb123 (LF), and rp17 and TmpA (yaws). Village-clustered seroprevalence was estimated by province and island in children aged 1–9 (trachoma, LF) and 1–14 years (yaws).Findings: Of 2,804 village-matched DBS, 2,738 had recorded age. In children aged 1–9 years, anti-Pgp3 seroprevalence on Tanna (Tafea) rose from 5·3% (2021) to 31·8% (2023); provincial seroconversion rates were 2·8–3·7 per 100 person-years. Provincial anti-Bm14 seroprevalence was ≤1·1% (island-level maximum 2·6%), whereas island-level anti-Wb123 reached 31·8% (Tanna) and 21·7% (Efate); no double-positives occurred in this age group. Twenty-one children aged 1–14 years were yaws seropositive (anti-rp17/anti-TmpA double-positive): 17 in Tafea (all Tanna) and four in Shefa (all Efate).Interpretation: Integrated multiplex serosurveillance generated concurrent data for three NTDs from a single DBS within routine programme activities, a first for Vanuatu. Findings support continued post-validation surveillance for trachoma and LF, identify Tafea as a yaws focus, and offer a replicable model for resource-limited settings.
- 15 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessIntegrated Serological Surveillance of Neglected Tropical Diseases in Elimination and Post-Elimination Pathways in Vanuatu
Background: Vanuatu was validated for elimination of lymphatic filariasis (LF) as a public health problem in 2016 and of trachoma in 2022, yet yaws remains endemic. Post-validation surveillance is poorly defined and disease-specific surveys costly. We assessed a multiplex serological platform embedded in prevalence surveys integrated with mass drug administration (MDA) using ivermectin, azithromycin and albendazole, as post-validation surveillance for trachoma and LF and to identify yaws transmission foci.Methods: Six cross-sectional surveys (2021–2024) in Tafea, Sanma and Shefa provinces accompanied integrated MDA. Dried blood spots (DBS) from randomly selected participants aged ≥1 year were tested by multiplex bead assay for IgG against Pgp3 (trachoma), Bm14 and Wb123 (LF), and rp17 and TmpA (yaws). Village-clustered seroprevalence was estimated by province and island in children aged 1–9 (trachoma, LF) and 1–14 years (yaws).Findings: Of 2,804 village-matched DBS, 2,738 had recorded age. In children aged 1–9 years, anti-Pgp3 seroprevalence on Tanna (Tafea) rose from 5·3% (2021) to 31·8% (2023); provincial seroconversion rates were 2·8–3·7 per 100 person-years. Provincial anti-Bm14 seroprevalence was ≤1·1% (island-level maximum 2·6%), whereas island-level anti-Wb123 reached 31·8% (Tanna) and 21·7% (Efate); no double-positives occurred in this age group. Twenty-one children aged 1–14 years were yaws seropositive (anti-rp17/anti-TmpA double-positive): 17 in Tafea (all Tanna) and four in Shefa (all Efate).Interpretation: Integrated multiplex serosurveillance generated concurrent data for three NTDs from a single DBS within routine programme activities, a first for Vanuatu. Findings support continued post-validation surveillance for trachoma and LF, identify Tafea as a yaws focus, and offer a replicable model for resource-limited settings.
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Immunology Research
- Vol. 2026 (1) , 7429749
C3d Complement Activation and Antibody Immunity in Convalescent COVID‐19: Insights From Adults and Children
Following severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, the complement pathway becomes activated, generating the stable split product C3d. Although C3d can modulate B cell responses through complement receptor 2 (CR2) in experimental systems, it remains unclear how circulating C3d relates to antibody responses after SARS‐CoV‐2 infection in humans. Here, we examined plasma C3d levels and their associations with SARS‐CoV‐2–specific antibody responses and clinical characteristics in convalescent adults and children. In adults, older age, male sex, and a history of severe COVID‐19 were independently associated with higher C3d levels. C3d concentrations positively correlated with receptor‐binding domain (RBD)‐specific antibody‐dependent cellular phagocytosis (ADCP), neutralizing antibody (nAb) titer, and anti‐spike IgM, IgG, IgG1, and IgG3 levels. In children, C3d levels were significantly lower than in adults and correlated with anti‐spike and anti‐RBD IgG titers. These findings demonstrate that systemic complement activation, reflected by circulating C3d, is positively associated with SARS‐CoV‐2 antibody responses in both age groups. As this cross‐sectional study cannot determine causality, further mechanistic and longitudinal studies are needed to define the role, if any, of C3d in shaping adaptive immunity to SARS‐CoV‐2.
- 1 January 2026
- Published by Wiley in Journal of Immunology Research
- Vol. 2026 (1) , 7429749
Open AccessC3d Complement Activation and Antibody Immunity in Convalescent COVID‐19: Insights From Adults and Children
Following severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, the complement pathway becomes activated, generating the stable split product C3d. Although C3d can modulate B cell responses through complement receptor 2 (CR2) in experimental systems, it remains unclear how circulating C3d relates to antibody responses after SARS‐CoV‐2 infection in humans. Here, we examined plasma C3d levels and their associations with SARS‐CoV‐2–specific antibody responses and clinical characteristics in convalescent adults and children. In adults, older age, male sex, and a history of severe COVID‐19 were independently associated with higher C3d levels. C3d concentrations positively correlated with receptor‐binding domain (RBD)‐specific antibody‐dependent cellular phagocytosis (ADCP), neutralizing antibody (nAb) titer, and anti‐spike IgM, IgG, IgG1, and IgG3 levels. In children, C3d levels were significantly lower than in adults and correlated with anti‐spike and anti‐RBD IgG titers. These findings demonstrate that systemic complement activation, reflected by circulating C3d, is positively associated with SARS‐CoV‐2 antibody responses in both age groups. As this cross‐sectional study cannot determine causality, further mechanistic and longitudinal studies are needed to define the role, if any, of C3d in shaping adaptive immunity to SARS‐CoV‐2.
- Open Access
- 10 April 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 81 (3) , 415-428
B-cell characteristics define HCV reinfection outcome
- 10 April 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 81 (3) , 415-428
Open AccessB-cell characteristics define HCV reinfection outcome
- Open Access
A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA (BNT162b2/mRNA-1273) and adenovirus vectored vaccines (ChAdOx1-S) after the first, second and third doses
We longitudinally profiled immune responses in 102 adults who received BNT162b2 (Pfizer-BioNTech) or ChAdOx1-S (Oxford-AstraZeneca) as their primary vaccinations. Bloods were collected pre-vaccination, 1-7 days after the 1 st , 2 nd and 3 rd doses (BNT162b2 or mRNA-1273) to assess innate and early adaptive responses, and ∼28 days after the 2 nd and 3 rd doses to assess immunogenicity. Using a multi-omics approach including RNAseq, cytokine multiplex assay, proteomics, lipidomics, and flow cytometry we identified key differences in the immune responses induced by the ChAdOx1-S and BNT162b2 vaccines that were correlated with subsequent antigen-specific antibody and T cell responses or vaccine reactogenicity. We observed that vaccination with ChAdOx1-S but not BNT162b2 induced a memory-like response after the first dose, which was correlated with the expression of several proteins involved in complement and coagulation. The COVID-19 Vaccine Immune Responses Study (COVIRS) thus represents a major resource to understand the immunogenicity and reactogenicity of these COVID-19 vaccines.
Open AccessA systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA (BNT162b2/mRNA-1273) and adenovirus vectored vaccines (ChAdOx1-S) after the first, second and third doses
We longitudinally profiled immune responses in 102 adults who received BNT162b2 (Pfizer-BioNTech) or ChAdOx1-S (Oxford-AstraZeneca) as their primary vaccinations. Bloods were collected pre-vaccination, 1-7 days after the 1 st , 2 nd and 3 rd doses (BNT162b2 or mRNA-1273) to assess innate and early adaptive responses, and ∼28 days after the 2 nd and 3 rd doses to assess immunogenicity. Using a multi-omics approach including RNAseq, cytokine multiplex assay, proteomics, lipidomics, and flow cytometry we identified key differences in the immune responses induced by the ChAdOx1-S and BNT162b2 vaccines that were correlated with subsequent antigen-specific antibody and T cell responses or vaccine reactogenicity. We observed that vaccination with ChAdOx1-S but not BNT162b2 induced a memory-like response after the first dose, which was correlated with the expression of several proteins involved in complement and coagulation. The COVID-19 Vaccine Immune Responses Study (COVIRS) thus represents a major resource to understand the immunogenicity and reactogenicity of these COVID-19 vaccines.
- Open Access
COVID-19 convalescents exhibit deficient humoral and T cell responses to variant of concern Spike antigens at 12 month post-infection
Background: The duration and magnitude of SARS-CoV-2 immunity after infection, especially with regard to the emergence of new variants of concern (VoC), remains unclear. Here, immune memory to primary infection and immunity to VoC was assessed in mild-COVID-19 convalescents one year after infection and in the absence of viral re-exposure or COVID-19 vaccination. Methods: Serum and PBMC were collected from mild-COVID-19 convalescents at ∼6 and 12 months after a COVID-19 positive PCR (n=43) and from healthy SARS-CoV-2-seronegative controls (n=15-40). Serum titers of RBD and Spike-specific Ig were quantified by ELISA. Virus neutralisation was assessed against homologous, pseudotyped virus and homologous and VoC live viruses. Frequencies of Spike and RBD-specific memory B cells were quantified by flow cytometry. Magnitude of memory T cell responses was quantified and phenotyped by activation-induced marker assay, while T cell functionality was assessed by intracellular cytokine staining using peptides specific to homologous Spike virus antigen and four VoC Spike antigens. Findings: At 12 months after mild-COVID-19, >90% of convalescents remained seropositive for RBD-IgG and 88.9% had circulating RBD-specific memory B cells. Despite this, only 51.2% convalescents had serum neutralising activity against homologous live-SARS-CoV-2 virus, which decreased to 44.2% when tested against live B.1.1.7, 4.6% against B.1.351, 11.6% against P.1 and 16.2%, against B.1.617.2 VoC. Spike and non-Spike-specific T cells were detected in >50% of convalescents with frequency values higher for Spike antigen (95% CI, 0.29-0.68% in CD4 + and 0.11-0.35% in CD8 + T cells), compared to non-Spike antigens. Despite the high prevalence and maintenance of Spike-specific T cells in Spike ‘high-responder’ convalescents at 12 months, T cell functionality, measured by cytokine expression after stimulation with Spike epitopes corresponding to VoC was severely affected. Interpretations: SARS-CoV-2 immunity is retained in a significant proportion of mild COVID-19 convalescents 12 months post-infection in the absence of re-exposure to the virus. Despite this, changes in the amino acid sequence of the Spike antigen that are present in current VoC result in virus evasion of neutralising antibodies, as well as evasion of functional T cell responses. Funding: This work was funded by project grants from The Hospital Research Foundation and Women’s and Children’s Hospital Foundation, Adelaide, Australia. MGM is THRF Early Career Fellow. BGB is THRF Mid-Career Fellow. This project has been supported partly with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00016 to A.S. and Contract No. 75N9301900065 to A.S, D.W. Evidence before this study: We regularly searched on PubMed and Google Scholar in June-October 2021 using individual or combinations of the terms “long-term immunity”, “SARS-CoV-2”, “antigenic breadth”, “variant of concern” and “COVID-19”. We found studies that had assessed immune correlates at multipe time points after COVID-19 disease onset in convalescents, but not the antigenic breadth of T cells and antibodies and not in relation to VoC. Other immune studies in virus naive vaccinees, or vaccinated convalescents evaluated VoC-specific immunity, but not in convalescents that have not been vaccinated. In summary, we could not find long-term studies providing and in-depth evaluation of functionality of humoral and cell-mediated immunity, combined with addressing the adaptability of these immune players to VoC. Added value of this study: The window of opportunity to conduct studies in COVID-19 convalescents (i.e. natural immunity to SARS-CoV-2) is closing due to mass vaccination programs. Here, in a cohort of unvaccinated mild-COVID-19 convalescents, we conducted a comprehensive, longitudinal, long-term immune study, which included functional assays to assess immune fitness against antigenically different VoC. Importantly, the cohort resided in a SARS-CoV-2-free community for the duration of the study with no subsequent re-exposure or infection. Our findings reveal a deeply weakened humoral response and functional vulnerability of T cell responses to VoC Spike antigens. Implications of all the available evidence: This study provides a valuable snapshot of the quality of SARS-CoV-2 natural immunity and its durability in the context of a pandemic in which new variants continuously emerge and challenge pre-existing immune responses in convalescents and vacinees. Our results serve as a warning that delays in vaccination programs could lead to an increase in re-infection rates of COVID-19 convalescents, caused by virus variants that escape humoral and cell-mediated immune responses. Furthermore, they reinforce the potential benefit of booster vaccination that is tuned to the active variants.
Open AccessCOVID-19 convalescents exhibit deficient humoral and T cell responses to variant of concern Spike antigens at 12 month post-infection
Background: The duration and magnitude of SARS-CoV-2 immunity after infection, especially with regard to the emergence of new variants of concern (VoC), remains unclear. Here, immune memory to primary infection and immunity to VoC was assessed in mild-COVID-19 convalescents one year after infection and in the absence of viral re-exposure or COVID-19 vaccination. Methods: Serum and PBMC were collected from mild-COVID-19 convalescents at ∼6 and 12 months after a COVID-19 positive PCR (n=43) and from healthy SARS-CoV-2-seronegative controls (n=15-40). Serum titers of RBD and Spike-specific Ig were quantified by ELISA. Virus neutralisation was assessed against homologous, pseudotyped virus and homologous and VoC live viruses. Frequencies of Spike and RBD-specific memory B cells were quantified by flow cytometry. Magnitude of memory T cell responses was quantified and phenotyped by activation-induced marker assay, while T cell functionality was assessed by intracellular cytokine staining using peptides specific to homologous Spike virus antigen and four VoC Spike antigens. Findings: At 12 months after mild-COVID-19, >90% of convalescents remained seropositive for RBD-IgG and 88.9% had circulating RBD-specific memory B cells. Despite this, only 51.2% convalescents had serum neutralising activity against homologous live-SARS-CoV-2 virus, which decreased to 44.2% when tested against live B.1.1.7, 4.6% against B.1.351, 11.6% against P.1 and 16.2%, against B.1.617.2 VoC. Spike and non-Spike-specific T cells were detected in >50% of convalescents with frequency values higher for Spike antigen (95% CI, 0.29-0.68% in CD4 + and 0.11-0.35% in CD8 + T cells), compared to non-Spike antigens. Despite the high prevalence and maintenance of Spike-specific T cells in Spike ‘high-responder’ convalescents at 12 months, T cell functionality, measured by cytokine expression after stimulation with Spike epitopes corresponding to VoC was severely affected. Interpretations: SARS-CoV-2 immunity is retained in a significant proportion of mild COVID-19 convalescents 12 months post-infection in the absence of re-exposure to the virus. Despite this, changes in the amino acid sequence of the Spike antigen that are present in current VoC result in virus evasion of neutralising antibodies, as well as evasion of functional T cell responses. Funding: This work was funded by project grants from The Hospital Research Foundation and Women’s and Children’s Hospital Foundation, Adelaide, Australia. MGM is THRF Early Career Fellow. BGB is THRF Mid-Career Fellow. This project has been supported partly with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00016 to A.S. and Contract No. 75N9301900065 to A.S, D.W. Evidence before this study: We regularly searched on PubMed and Google Scholar in June-October 2021 using individual or combinations of the terms “long-term immunity”, “SARS-CoV-2”, “antigenic breadth”, “variant of concern” and “COVID-19”. We found studies that had assessed immune correlates at multipe time points after COVID-19 disease onset in convalescents, but not the antigenic breadth of T cells and antibodies and not in relation to VoC. Other immune studies in virus naive vaccinees, or vaccinated convalescents evaluated VoC-specific immunity, but not in convalescents that have not been vaccinated. In summary, we could not find long-term studies providing and in-depth evaluation of functionality of humoral and cell-mediated immunity, combined with addressing the adaptability of these immune players to VoC. Added value of this study: The window of opportunity to conduct studies in COVID-19 convalescents (i.e. natural immunity to SARS-CoV-2) is closing due to mass vaccination programs. Here, in a cohort of unvaccinated mild-COVID-19 convalescents, we conducted a comprehensive, longitudinal, long-term immune study, which included functional assays to assess immune fitness against antigenically different VoC. Importantly, the cohort resided in a SARS-CoV-2-free community for the duration of the study with no subsequent re-exposure or infection. Our findings reveal a deeply weakened humoral response and functional vulnerability of T cell responses to VoC Spike antigens. Implications of all the available evidence: This study provides a valuable snapshot of the quality of SARS-CoV-2 natural immunity and its durability in the context of a pandemic in which new variants continuously emerge and challenge pre-existing immune responses in convalescents and vacinees. Our results serve as a warning that delays in vaccination programs could lead to an increase in re-infection rates of COVID-19 convalescents, caused by virus variants that escape humoral and cell-mediated immune responses. Furthermore, they reinforce the potential benefit of booster vaccination that is tuned to the active variants.